These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 25742653)

  • 21. Molecular and component volumes of saturated n-alkanols in DOPC+DOPS bilayers.
    Klacsová M; Westh P; Balgavý P
    Chem Phys Lipids; 2010 Jun; 163(6):498-505. PubMed ID: 20399763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal production of L-threo-2,3-dihydroxyphenylserine (L-threo-DOPS) on a large scale by diastereoselectivity-enhanced variant of L-threonine aldolase expressed in Escherichia coli.
    Gwon HJ; Yoshioka H; Song NE; Kim JH; Song YR; Jeong DY; Baik SH
    Prep Biochem Biotechnol; 2012; 42(2):143-54. PubMed ID: 22394063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.
    Fukada K; Endo T; Yokoe M; Hamasaki T; Hazama T; Sakoda S
    Med Hypotheses; 2013 Feb; 80(2):209-12. PubMed ID: 23265352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein G-liposomal nanovesicles as universal reagents for immunoassays.
    Chen CS; Baeumner AJ; Durst RA
    Talanta; 2005 Jul; 67(1):205-11. PubMed ID: 18970156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi trigger responsive, surface active lipid nanovesicle aerosols for improved efficacy of paclitaxel in lung cancer.
    Joshi N; Kaviratna A; Banerjee R
    Integr Biol (Camb); 2013 Jan; 5(1):239-48. PubMed ID: 22911380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting claudin-4 in human pancreatic cancer.
    Kojima T; Kyuno D; Sawada N
    Expert Opin Ther Targets; 2012 Sep; 16(9):881-7. PubMed ID: 22800288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of L-threo-DOPS on P-300 in parkinsonism].
    Yokota J; Itoh T; Imai H; Narabayashi H
    Rinsho Shinkeigaku; 1990 May; 30(5):499-504. PubMed ID: 2119267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells.
    Fu SL; Pierre J; Smith-Norowitz TA; Hagler M; Bowne W; Pincus MR; Mueller CM; Zenilman ME; Bluth MH
    Clin Exp Immunol; 2008 Sep; 153(3):401-9. PubMed ID: 18803764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
    Ogawa N; Yamamoto M; Takayama H
    J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction: Tetrahydrocurcumin protects against cadmium-induced hypertension, raised arterial stiffness and vascular remodeling in mice.
    PLOS ONE Staff
    PLoS One; 2015; 10(3):e0118755. PubMed ID: 25742657
    [No Abstract]   [Full Text] [Related]  

  • 31. Correction: Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer.
    PLOS ONE Staff
    PLoS One; 2015; 10(3):e0118232. PubMed ID: 25742653
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer.
    Chu Z; Abu-Baker S; Palascak MB; Ahmad SA; Franco RS; Qi X
    PLoS One; 2013; 8(10):e75507. PubMed ID: 24124494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of cancer cells using SapC-DOPS nanovesicles.
    Davis HW; Hussain N; Qi X
    Mol Cancer; 2016 May; 15(1):33. PubMed ID: 27160923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SapC-DOPS nanovesicles as targeted therapy for lung cancer.
    Zhao S; Chu Z; Blanco VM; Nie Y; Hou Y; Qi X
    Mol Cancer Ther; 2015 Feb; 14(2):491-8. PubMed ID: 25670331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxicity and Selectivity in Skin Cancer by SapC-DOPS Nanovesicles.
    Abu-Baker S; Chu Z; Stevens AM; Li J; Qi X
    J Cancer Ther; 2012 Aug; 3(4):321-326. PubMed ID: 25485166
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.